Search

Your search keyword '"Fagerli, Unn Merete"' showing total 124 results
Start Over Author "Fagerli, Unn Merete" Language english
124 results on '"Fagerli, Unn Merete"'

6. Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis

Author

Leppä, Sirpa, Jørgensen, Judit, Tierens, Anne, Meriranta, Leo, Østlie, Ingunn, de Nully Brown, Peter, Fagerli, Unn-Merete, Larsen, Thomas Stauffer, Mannisto, Susanna, Munksgaard, Lars, Maisenhölder, Martin, Vasala, Kaija, Meyer, Peter, Jerkeman, Mats, Björkholm, Magnus, Fluge, Øystein, Jyrkkiö, Sirkku, Liestøl, Knut, Ralfkiaer, Elisabeth, Spetalen, Signe, Beiske, Klaus, Karjalainen-Lindsberg, Marja-Liisa, and Holte, Harald

Published
2020
Full Text
View/download PDF

10. Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years

Author

Kolstad, Arne, Pedersen, Lone Bredo, Eskelund, Christian W., Husby, Simon, Grønbæk, Kirsten, Jerkeman, Mats, Laurell, Anna, Räty, Riikka, Elonen, Erkki, Andersen, Niels Smedegaard, Brown, Peter deNully, Kimby, Eva, Bentzen, Hans, Sundström, Christer, Ehinger, Mats, Karjalainen-Lindsberg, Marja-Liisa, Delabie, Jan, Ralfkiær, Elisabeth, Fagerli, Unn-Merete, Nilsson-Ehle, Herman, Lauritzsen, Grete Fossum, Kuittinen, Outi, Niemann, Carsten, and Geisler, Christian Hartman

Published
2017
Full Text
View/download PDF

11. Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma

Author

Kolstad, Arne, Laurell, Anna, Jerkeman, Mats, Grønbæk, Kirsten, Elonen, Erkki, Räty, Riikka, Pedersen, Lone Bredo, Loft, Annika, Bogsrud, Trond Velde, Kimby, Eva, Hansen, Per Boye, Fagerli, Unn-Merete, Nilsson-Ehle, Herman, Lauritzsen, Grete Fossum, Lehmann, Anne Kristine, Sundstrom, Christer, Karjalainen-Lindsberg, Marja-Liisa, Ralfkiaer, Elisabeth, Ehinger, Mats, Delabie, Jan, Bentzen, Hans, Schildt, Jukka, Kostova-Aherdan, Kamelia, Frederiksen, Henrik, Brown, Peter de Nully, and Geisler, Christian H.

Published
2014
Full Text
View/download PDF

15. Total late effect burden in long-term lymphoma survivors after high-dose therapy with autologous stem-cell transplant and its effect on health-related quality of life

Author

Smeland, Knut Bjøro, Holte, Harald, Fagerli, Unn-Merete, Bersvendsen, Hanne Skjerven, Hjermstad, Marianne Jensen, Loge, Jon Håvard, Murbræch, Klaus, Linnsund, Marianne Dahl, Fluge, Øystein, Stenehjem, Jo Steinson, Samersaw-Lund, May Brit, Kvaløy, Stein Olav, and Kiserud, Cecilie E.

Subjects
Adult, Lymphoma, Quality of Life, Hematopoietic Stem Cell Transplantation, Humans, Female, Survivors, Hematology, Transplantation, Autologous
Abstract

Lymphoma survivors after high-dose therapy with autologous stem-cell transplant (HDT-ASCT) are at risk of several late effects, which might impair their health-related quality of life (HRQoL). We assessed the total late effect burden in this population, and how it affects HRQoL. All lymphoma survivors treated with HDT-ASCT as adults in Norway between 1987 and 2008 were identified, and 271 (68%) attended both a comprehensive clinical assessment and completed a questionnaire. Severity of 45 conditions in 12 organ-system categories were graded as mild, moderate, severe or life-threatening, according to a modified version of CTCAEv4.03. At a median of 8 years after HDT-ASCT, 98% of survivors had at least one moderate or more severe late effect and 56% had severe or life-threatening late effects. Fourteen percent had low, 39% medium and 47% high late effect burden, defined as having moderate or more severe late effects in 0-1, 2-3 and >3 organsystems, respectively. Female sex, increasing age, B-symptoms at diagnosis and >1 treatment line prior to HDT-ASCT were independently associated with having high late effect burden. The survivors had significantly poorer physical and mental HRQoL assessed by the Short Form-36 compared to age- and sex-matched controls. The prevalence of poor physical and mental HRQoL increased with higher late effect burden (both P

Published
2022

17. Chronic fatigue in long-term survivors of Hodgkin's lymphoma after contemporary risk-adapted treatment.

Author

Eikeland, Siri A., Smeland, Knut B., Simensen, Victoria Charlotte, Fagerli, Unn-Merete, Bersvendsen, Hanne S., Kiserud, Cecilie E., and Fosså, Alexander

Subjects
HODGKIN'S disease treatment, CANCER patient psychology, HODGKIN'S disease, STATISTICS, UNEMPLOYMENT, CROSS-sectional method, MULTIVARIATE analysis, MULTIPLE regression analysis, WORK capacity evaluation, HEALTH surveys, RISK assessment, SURVIVAL rate, SEX distribution, CANCER fatigue, SOCIAL classes, QUESTIONNAIRES, DESCRIPTIVE statistics, BODY mass index, RADIOTHERAPY, CHRONIC fatigue syndrome, MENTAL fatigue, COMORBIDITY, EDUCATIONAL attainment, LONGITUDINAL method, DISEASE risk factors, DISEASE complications
Abstract

Chronic fatigue (CF), substantial fatigue for ≥ six months, can manifest as a late effect (LE) after cancer treatment, and may affect several aspects of life. In a Norwegian cohort of Hodgkin's lymphoma survivors (HLS), more than a decade after contemporary risk-adapted treatment regimens with limited use of radiotherapy (RT), we assessed: (1) Prevalence of, (2) factors associated with (3) and implications of CF on socioeconomic status (SES) and work ability (WA). HLS treated between 1997–2006, aged 8–49 years at diagnosis, were invited to participate in a population-based cross-sectional study on late effects in 2018–2019. In a mailed questionnaire, HLS responded to a fatigue questionnaire (FQ), work ability score (WAS) and short-form health survey (SF-36). Disease- and treatment data were extracted from hospital records. Factors associated with CF were identified by uni- and multivariate analysis. To study the implications of CF on SES and WA, a multinomial regression analysis was performed. Invitations were extended to 518 HLS and 298 (58%) responded to FQ, of whom 42% had CF with mean (standard deviation [SD]) physical- and mental fatigue scores of 10.2 (4.3) and 5.5 (2.1) respectively. Median age at survey was 45 years, 47% were females. In multivariate analysis female sex (p = 0.03), lower education (p = 0.03), body mass index ≥30 kg/m2 (p = 0.04), and an increasing number of comorbidities (p = 0.01) were associated with CF. No association with disease stage, chemotherapy or RT was found. CF was associated with poorer WAS scores at survey (p < 0.001), unemployment (p = 0.03), and receiving disability pension (p = 0.003). After risk-adapted treatment, CF is still a frequent LE among long-term HLS, without apparent association with disease or treatment-related parameters. CF is associated with reduced WA and SES. As no apparent risk reduction is seen with contemporary treatment, further studies should emphasize etiological factors of CF and treatment to alleviate this common LE. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

24. Biomarker-Driven Treatment Strategy in High-Risk Large B-Cell Lymphoma: Final Results of a Nordic Phase 2 Study

Author

Leppa, Sirpa, Jørgensen, Judit M., Karjalainen-Lindsberg, Marja-Liisa, Beiske, Klaus, Pedersen, Mette, Drott, Kristina, Pasanen, Annika, Karihtala, Kristiina, Mannisto, Susanna, Meriranta, Leo, Wold, Bente, Brodtkorb, Marianne, Fagerli, Unn Merete, Larsen, Thomas S., Munksgaard, Lars, Sunela, Kaisa, Fluge, Øystein, Jyrkkio, Sirkku, Brown, Peter de Nully, and Holte, Harald

Published
2022
Full Text
View/download PDF

25. Long-Term Follow-up of Clinical Outcome Determinants and Correlative Biological Features from the Nordic NLG-T-01 Trial

Author

Relander, Thomas, Pedersen, Martin Bjerregård, Ellin, Fredrik, Lauritzsen, Grete Fossum, Jantunen, Esa, Hagberg, Hans, Holte, Harald, Österborg, Anders, Brown, Peter De Nully, Kuittinen, Outi, Erlanson, Martin, Ostenstad, Bjorn, Fagerli, Unn-Merete, Delabie, Jan, Sundström, Christer, Sander, Birgitta, Hamilton-Dutoit, Stephen, Ehinger, Mats, Liestol, Knut, Toldbod, Helle, Feldman, Andrew L., and d'Amore, Francesco Annibale

Published
2022
Full Text
View/download PDF

26. Using blood calprotectin as a measure of blood neutrophils.

Author

Åsberg, Arne, Løfblad, Lena, Felic, Amela, Aune, Marthe Wedø, Hov, Gunhild Garmo, and Fagerli, Unn Merete

Subjects
CALPROTECTIN, PROTEINS, NEUTROPHILS, ANTINEOPLASTIC agents, DRUG therapy
Abstract

Presently, bed-side or at home quantification of neutrophils in blood (b-neutrophils) is not practical, because cytometric methods are too expensive and technically demanding. We have explored whether calprotectin concentration in whole blood (b-calprotectin) might be a valid measure of b-neutrophils because this principle might be used in a simple and robust immunoassay device. We obtained heparin blood samples from 77 patients with possible neutropenia, most of them cancer patients treated with cytostatic drugs, and compared b-calprotectin with their b-neutrophils in a simultaneously taken EDTA-blood sample. The Spearman rank correlation coefficient between b-calprotectin and b-neutrophils was 0.986 (p <.0001). In a regression model of b-neutrophils as a function of age, gender, type of hematology instrument, total leukocyte count minus neutrophils, b-calprotectin, and plasma calprotectin (p-calprotectin), only b-calprotectin was a statistically significant predictor. B-neutrophils below 1 × 109/L was unlikely if b-calprotectin was above 50 mg/L. In conclusion, b-calprotectin, without adjusting for p-calprotectin, correlates closely with b-neutrophils and could be used to detect b-neutrophils below 1 × 109/L. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

27. Chemotherapy-induced peripheral neuropathy after modern treatment of Hodgkin's lymphoma; symptom burden and quality of life.

Author

Eikeland, Siri A., Smeland, Knut B., Mols, Floortje, Fagerli, Unn-Merete, Bersvendsen, Hanne S., Kiserud, Cecilie E., and Fosså, Alexander

Subjects
HODGKIN'S disease, PERIPHERAL neuropathy, CANCER chemotherapy, MULTIVARIATE analysis, HEALTH surveys, REGRESSION analysis, SEVERITY of illness index, CANCER patients, QUALITY of life, DISEASE prevalence, QUESTIONNAIRES, DESCRIPTIVE statistics, COMORBIDITY
Abstract

Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting side effect of Hodgkin's lymphoma (HL) treatment. We aimed to describe the prevalence of CIPN associated symptoms in long-term HL survivors compared to controls, and determine associated factors, including impact on health-related quality of life (HRQoL). A questionnaire, including EORTC QLQ-CIPN-20 for CIPN related symptoms and SF-36 for HRQoL, was completed by 303 HL survivors at a median of 16 years after diagnosis. CIPN results were compared to a normative population (n = 606). CIPN associated factors were identified by linear regression analysis. Total CIPN score and subscores were significantly higher in HL survivors compared to controls. In multivariate analysis of HL survivors, a number of comorbidities (p < 0.001) and female gender (p = 0.05) were significantly associated with more CIPN. No association with disease or treatment factors was found. In a multivariate analysis including survivors and controls, the number of comorbidities (p < 0.001) and caseness (p < 0.001) were significantly associated with more CIPN. In HL survivors higher CIPN score was associated with reduced HRQoL (p < 0.001). HL survivors more than a decade after treatment report higher neuropathy-related symptom burden than controls, with a negative impact on HRQoL. Symptoms may be related to factors other than neurotoxic chemotherapy. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

28. Runaway Train: A Leaky Radiosensitive SCID with Skin Lesions and Multiple Lymphomas

Author

Fevang, Børre, Fagerli, Unn Merete, Sorte, Hanne, Aarset, Harald, Hov, Håkon, Langmyr, Marit, Keil, Thomas Morten, Bjørge, Ellen, Aukrust, Pål, Stray-Pedersen, Asbjørg, and Gedde-Dahl, Tobias

Subjects
Article Subject
Abstract

The nuclease Artemis is essential for the development of T-cell and B-cell receptors and repair of DNA double-strand breaks, and a loss of expression or function will lead to a radiosensitive severe combined immunodeficiency with no functional T-cells or B-cells (T-B-SCID). Hypomorphic mutations in the Artemis gene can lead to a functional, but reduced, T-cell and B-cell repertoire with a more indolent clinical course called “leaky” SCID. Here, we present the case of a young man who had increasingly aggressive lymphoproliferative skin lesions from 2 years of age which developed into multiple EBV+ B-cell lymphomas, where a hypomorphic mutation in the Artemis gene was found in a diagnostic race against time using whole exome sequencing. The patient was given a haploidentical stem cell transplant while in remission for his lymphomas and although the initial course was successful, he succumbed to a serious Pneumocystis jirovecii pneumonia 5 months after the transplant. The case underscores the importance of next-generation sequencing in the diagnosis of patients with suspected severe immunodeficiency.

Published
2018
Full Text
View/download PDF

29. Brentuximab vedotin in relapsed or refractory classical hodgkin lymphoma: real life experience in Norway 2011–2016.

Author

Fosså, Alexander, Smeland, Knut, Fagerli, Unn-Merete, Galleberg, Renate B., Bersvendsen, Hanne S., and Holte, Harald

Subjects
HODGKIN'S disease treatment, THERAPEUTIC use of monoclonal antibodies, CANCER relapse, COMBINATION drug therapy, CHI-squared test, CONFIDENCE intervals, HEMATOPOIETIC stem cell transplantation, HODGKIN'S disease, IMIDAZOLES, MONOCLONAL antibodies, POSTOPERATIVE period, TREATMENT effectiveness, RETROSPECTIVE studies, KAPLAN-Meier estimator, LOG-rank test, MANN Whitney U Test, DISEASE risk factors
Abstract

The article describes the experience with Brentuximab vedotin (BV) antibody-drug conjugate in r/r cHL in Norway for patients treated with the approved indications from 2011 to 2016. Highlights include consolidation of responses to BV achieved through radiotherapy in isolated patients, approval of the study by the South East Regional Committee for Medical and Health Research Ethics, and comparison of patients treated with BV and a population-based historical cohort.

Published
2020
Full Text
View/download PDF

30. Survivors' knowledge of their diagnosis, treatment and possible late adverse effects after autologous stem cell transplantation for lymphoma.

Author

Simensen, Victoria C., Smeland, Knut B., Kiserud, Cecilie E., Dahl, Alv A., Bersvendsen, Hanne S., Fluge, Øystein, Fagerli, Unn-Merete, and Fosså, Alexander

Subjects
LYMPHOMA diagnosis, STEM cell transplantation, AGE distribution, CANCER patients, EXPERIENCE, PATIENT aftercare, INTERVIEWING, LYMPHOMAS, RESEARCH methodology, MENTAL health, MULTIVARIATE analysis, QUALITY of life, REGRESSION analysis, HEALTH literacy, ADVERSE health care events
Abstract

Purpose: Lymphoma survivors after high dose therapy with autologous stem cell therapy (HD-ASCT) are at high risk for late adverse effects (AEs). Information patients receive and collect throughout their cancer trajectory about diagnosis, treatment schedule and risks of AEs may influence attitudes and health-related behavior in the years after treatment. The purpose of this study was to explore level of knowledge in lymphoma survivors after HD-ASCT at a median of 12 years after primary diagnosis. Material and methods: From a national study on the effects of HD-ASCT for lymphomas, 269 survivors met for an outpatient examination, including a structured interview addressing knowledge about diagnosis and treatment. Survivors were also asked whether they knew and/or had experienced certain common late AEs. Numbers of recognized and experienced late AEs were presented as sum scores. Factors associated with the level of knowledge of late AEs were analyzed by linear regression analysis. Results: Eighty-one percent of the survivors knew their diagnosis, 99% knew the components of HD-ASCT and 97% correctly recalled having had radiotherapy. Ninety percent reported awareness of late AEs, but the level of knowledge and personal experience with specified AEs varied. Thirty-five percent of survivors stated to have received follow-up for late AEs. In multivariable analysis younger age at diagnosis, having received mediastinal radiotherapy, higher mental health related quality of life, a higher number of self-experienced late AEs and having received follow-up care for late AEs were significantly associated with a higher level of knowledge of AEs. Conclusion: The majority of lymphoma survivors treated with HD-ASCT correctly recalled diagnosis and treatment, while knowledge of late AEs varied. Our findings point to information deficits in survivors at older age and with lower mental health related quality of life. They indicate benefit of follow-up to enhance education on late AEs in lymphoma survivors. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

31. Lifestyle behavior among lymphoma survivors after high-dose therapy with autologous hematopoietic stem cell transplantation, assessed by patient-reported outcomes.

Author

Bersvendsen, Hanne Skjerven, Haugnes, Hege Sagstuen, Fagerli, Unn-Merete, Fluge, Øystein, Holte, Harald, Smeland, Knut Bjøro, Wilsgaard, Tom, and Kiserud, Cecilie Essholt

Subjects
LYMPHOMA treatment, AGE distribution, AUTOTRANSFUSION of blood, CANCER chemotherapy, ALCOHOL drinking, FATIGUE (Physiology), HEALTH behavior, HEMATOPOIETIC stem cell transplantation, INCOME, MENTAL illness, MULTIVARIATE analysis, OBESITY, HEALTH outcome assessment, SEX distribution, SMOKING, SOCIAL isolation, LOGISTIC regression analysis, LIFESTYLES, CROSS-sectional method, SEDENTARY lifestyles, PHYSICAL activity, DESCRIPTIVE statistics
Abstract

Introduction: High-dose therapy with autologous stem cell transplantation (HD-ASCT) is associated with an increased risk of late effects. Our aim was to assess lifestyle behavior and factors associated with unhealthy lifestyle among HD-ASCT-treated lymphoma survivors (HD-ASCT-LS). Materials and methods: We conducted a national cross-sectional study of HD-ASCT-LS treated during 1987–2008. Among 399 eligible participants, 312 (78%) completed patient-reported outcome measures (PROMs) on lifestyle behavior (physical activity, overweight, smoking and alcohol consumption), chronic fatigue (CF) and somatic and mental illness. We assessed lifestyle according to WHO recommendations. Multivariable logistic regression models were used to study associations between variables. A comparison to the general population was performed. Results: Mean age at survey was 54.6 years, 60% were men, 55% sedentary, 55% overweight, 18% smokers and 5% had unhealthy alcohol consumption. Being sedentary was positively associated with older age, low household income, CF and higher somatic burden (≥4 self-reported somatic conditions). Overweight was positively associated with male gender and negatively associated with increased number of chemotherapy regimens prior to HD-ASCT. Current smoking was positively associated with living alone and CF, and negatively associated with older age. Male gender, CF and higher somatic burden increased the risk of an unhealthier lifestyle whereas the increased number of chemotherapy regimens prior to HD-ASCT decreased the risk. HD-ASCT-LS were significantly less sedentary, less overweight, and had a lower likelihood of smoking than the controls. Discussion: Assessed by PROMs, unhealthy habits were frequent among HD-ASCT-LS and associated with comorbidity. Nevertheless, compared with controls significantly more HD-ASCT-LS met lifestyle recommendations. These results indicate that the HD-ASCT-LS may consist of two groups, the adhering group with less comorbidity and the non-adhering group with more comorbidity. Our findings illustrate the necessity of recommendations and support for improving health-related behavior in cancer survivorship plans in order to empower survivors in their life beyond cancer. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

33. LYMRIT 37-01: A Phase I/II Study of 177lu-Lilotomab Satetraxetan (Betalutin®) Antibody-Radionuclide-Conjugate (ARC) for the Treatment of Relapsed Non-Hodgkin's Lymphoma (NHL) — Analysis with 6-Month Follow-up

Author

Kolstad, Arne, Madsbu, Ulf, Beasley, Matthew, Bayne, Michael, Illidge, Tim M., O'Rourke, Noelle, Lagerlöf, Ingemar, Hajek, Roman, Jurczak, Wojciech, Willenbacher, Ella, Fagerli, Unn Merete, Obr, Aleš, Blakkisrud, Johan, Muftuler Løndalen, Ayca, Rojkjaer, Lisa, Østengen, Åse, Bolstad, Nils, Spetalen, Signe, Erlanson, Martin, Galleberg, Renate, Nygaard Rudå, Stine, and Holte, Harald, Jr.

Published
2018
Full Text
View/download PDF

34. Final Analysis of the Front-Line Phase III Randomized ACT-1 Trial in Younger Patients with Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated By Autologous Hematopoietic Stem Cell Transplant

Author

d'Amore, Francesco, Leppä, Sirpa, Silva, Maria Gomes da, Relander, Thomas, Lauritzsen, Grete Fossum, Brown, Peter De Nully, Pezzutto, Antonio, Doorduijn, Jeanette K., Weidmann, Eckhart, van Gelder, Michel, Hoof, Achiel Van, Christiansen, Ilse, Fagerli, Unn Merete, Hagberg, Hans, Lugtenburg, P.J., Walewski, Jan, Wu, Ka Lung, Demuynck, Hilde Maria, Fijnheer, Rob, Christensen, Jacob H., Jankovská, Milada, Josefsson, Pär L., Kluin-Nelemans, Hanneke, Mariz, Jose Mario, Merup, Mats A., Noesslinger, Thomas, Van Den Neste, Eric, Zijlstra, Josée M, Hopfinger, Georg, Prochazka, VIT, Jantunen, Esa, Boudova, Ludmila, Cabecadas, Jose, Chott, Andreas, Delabie, Jan M.A., de Leval, Laurence, Diepstra, Arjan, Karjalainen-Lindsberg, Marja-Liisa, Noergaard, Peter, Rosenwald, Andreas, Rymkiewicz, Grzegorz, Sundström, Christer, Truemper, Lorenz, Wulf, Gerald, Chong, Lauren, Bouska, Alyssa, Smith, Lynette, Gisselbrecht, Christian, Ziepert, Marita, Loeffler, Markus, Liestol, Knut, Steidl, Christian, Gascoyne, Randy D., Scott, David W., Altmann, Bettina, Iqbal, Javeed, Chan, Wing C, and Toldbod, Helle

Published
2018
Full Text
View/download PDF

36. 90y-Ibritumumab Tiuxetan (Zevalin®-BEAM/C with Autologous Stem Cell Support as Therapy for Advanced Mantle Cell Lymphoma. - Preliminary Results From the Third Nordic II Study (MCL3)

Author

Kolstad, Arne, Laurell, Anna, Andersen, Niels S, Elonen, Erkki, Raty, Riikka, Pedersen, Lone Bredo, Bogsrud, Annik Trond Velde, Nordstrom, Marie, Gillström, Dorte Balle, Hansen, Per Boye, Bentzen, Hans, Fagerli, Unn-Merete, Meyer, Peter, Nilsson-Ehle, Herman, Jerkeman, Mats, Lehman, Anne Kristine, Lauritzen, Grete F, Sundstrom, Christer, Delabie, Jan, Karjaalainen-Lindsberg, Marja-Liisa, Ralfkiaer, Elisabeth, Ehinger, Mats, and Geisler, Christian H.

Abstract

The Nordic Lymphoma Group has since 1996 conducted three consecutive phase II trials for front-line treatment of MCL patients ≤ 65 years of age. The first protocol (MCL1) 1996-2000 introduced high-dose chemotherapy with autologous stem cell support (unpurged or ex vivo purged) as consolidation after 4 cycles of intensified CHOP (maxi-CHOP). The results were disappointing, as the majority of patients relapsed. 1 Being in CR pre-transplant was the most important factor for outcome. Hence, in the second trial (MCL2) 2000-2006 induction therapy was intensified by adding high-dose Ara-C and rituximab to the regimen. Compared to MCL1 this led to significant improvement of event-free and overall survival, and the rate of PCR negative stem cell grafts and bone marrow samples.2 Again, responders in less than CR pre-transplant had a significantly poorer outcome. We therefore made a further intensification for the MCL3 study (2006-2009) by adding 90Y-Ibritumomab tiuxetan (Zevalin ®) to the high-dose BEAC/BEAM to responders not in CR. Methods: As in the MCL1 and 2 studies newly diagnosed stage II-IV MCL patients ≤ 65 years were included. Induction treatment was identical to that of the MCL2 study with alternating cycles of maxi-CHOP-rituximab (3 cycles) and Ara-C-rituximab (3 cycles). Response evaluation was done after cycle 5. PET/CT was recommended, but could not influence the response evaluation, which was done according to the International Workshop criteria. Responders underwent in vivo purged harvest of stem cells after cycle 6 (Ara-C + 2 doses of rituximab). Patients in CRu or PR received a standard dose 90Y-Ibritumomab tiuxetan (0.4 mCi/kg) one week prior to the BEAM/BEAC, CR patients received BEAM/BEAC alone. Patients are followed by CT-scans, bone marrow and blood samples, including PCR for minimal residual disease or molecular relapse. For molecular relapse preemptive treatment with 4 standard doses of rituximab, as in the MCL2 study3, is given. Results: The planned accrual of 160 patients was reached in June 2009. The patient characteristics are similar to those of the MCL2 trial with a median age of 57 years (28-65), the majority male (80%) and in stage IV (89%) with bone marrow involvement (74%). The response rates pre-transplant so far compare favorably with data from MCL2 with 50% in CR, 18% in CRu, and 28% in PR. Only 4 out of 128 evaluable patients did not respond (3%) and there was one case (1%) of treatment-related mortality during induction therapy. While it is still too early to assess the impact of the 90Y-Ibritumomab tiuxetan on the progression-free survival, the side effects were similar to those of the MCL2 study including a treatment related mortality of 4%. Fifty-five patients in CRu or PR have so far been treated with 90Y-Ibritumomab tiuxetan, with no indication of any added toxicity. Only 12 out of 133 patients (10%) have not undergone transplant, 5 due to stem cell harvest failure, 3 due to toxicity and 4 due to non response to induction treatment. PET-scan prior to transplant was positive in 2% of CR patients, 20% of CRu patients and 54% of PR patients. Patients with a positive PET-scan pre-transplant had a 36% chance of achieving a molecular remission post-transplant, compared to 92% of cases with a negative PET-scan (pConclusion: The high response rates after induction treatment achieved in the MCL2 study are confirmed in the present study. Adding 90Y-Ibritumomab tiuxetan to high-dose chemotherapy for responding patients not in CR prior to transplant is feasible and does not increase toxicity. A negative PET-scan prior to transplant predicts for a molecular remission after the transplant.References:1. Andersen et al, Eur J Cancer, 2002, 38: 401-4082. Geisler et al, Blood, 2008, 112: 2687-26933. Andersen et al J Clin Oncol 2009 epub ahead of press

Published
2009

37. 177 Lu-Lilotomab Satetraxetan, a Novel CD37-Targeted Antibody-Radionuclide Conjugate in Relapsed Non-Hodgkin's Lymphoma (NHL): Updated Results of an Ongoing Phase I/II Study (LYMRIT 37-01)

Author

Kolstad, Arne, Madsbu, Ulf, Beasley, Matthew, Bayne, Michael, Illidge, Tim M., O'Rourke, Noelle, Lagerlöf, Ingemar, Hájek, Roman, Jurczak, Wojciech, Willenbacher, Ella, Blakkisrud, Johan, Muftuler Løndalen, Ayca, Rojkjaer, Lisa, Baylor Curtis, Laurie, Bloma, Marianne, Turner, Simon, Bolstad, Nils, Spetalen, Signe, Erlanson, Martin, Fagerli, Unn Merete, Galleberg, Renate, Nygaard Rudå, Stine, and Holte, Harald

Published
2017
Full Text
View/download PDF

38. Dose-Dense Chemoimmunotherapy Including Early CNS Prophylaxis for High-Risk DLBCL. -Final Analysis from a Nordic Phase II Study (the CHIC trial)

Author

Leppa, Sirpa, Joergensen, Judit, Tierens, Anne, Østlie, Ingunn, Fagerli, Unn Merete, Brown, Peter de Nully, Larsen, Thomas S, Mannisto, Susanna, Munksgaard, Lars, Maisenhölder, Martin, Vasala, Kaija, Meyer, Peter, Jerkeman, Mats, Bjorkholm, Magnus, Fluge, Oystein, Jyrkkio, Sirkku, Ralfkiaer, Elisabeth, Spetalen, Signe, Karjalainen-Lindsberg, Marja-Liisa, and Holte, Harald

Published
2016
Full Text
View/download PDF

39. Up-Front Autologous Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: NLG-T-01.

Author

d'Amore, Francesco, Relander, Thomas, Lauritzsen, Grete F., Jantunen, Esa, Hagberg, Hans, Anderson, Harald, Holte, Harald, Österborg, Anders, Merup, Mats, Brown, Peter, Kuittinen, Outi, Erlanson, Martin, Østenstad, Bjørn, Fagerli, Unn-Merete, Gadeberg, Ole V., Sundström, Christer, Delabie, Jan, Ralfkiaer, Elisabeth, Vornanen, Martine, and Toldbod, Helle E.

Published
2012
Full Text
View/download PDF

40. First Interim Efficacy and Safety Analysis of an International Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with Chemotherapy with or without Alemtuzumab and Consolidated by High Dose Therapy

Author

d'Amore, Francesco, Leppä, Sirpa, da Silva, Maria Gomes, Relander, Thomas, De Nully Brown, Peter, Weidmann, Eckhart, Lauritzsen, Grete Fossum, Pezzutto, Antonio, Van Hoof, Achiel, van Gelder, Michel, Doorduijn, Jeanette K, Wu, Ka Lung, Kluin-Nelemans, J.C., Lugtenburg, P.J., Jankovska, Milada, Merup, Mats, Fagerli, Unn-Merete, Walewski, Jan, Hagberg, Hans, Mariz, Jose Mario, Hansen, Per Boye, Nösslinger, Thomas, Janssens, Ann, Brandefors, Lena, Demuynck, Hilde, Schaafsma, Martyn Ronald, Christiansen, Ilse, Salek, David, Jyrkkiö, Sirkku, Prochazka, Vit, Zijlstra, Josee, Böhmer, L., Greil, Richard, Stevens, Wendy, Fijnheer, Rob, van Marwijk Kooy, Marinus, Grube, Matthias, Hopfinger, Georg, Van den Neste, Eric, Jantunen, Esa, Trümper, Lorenz, Wulf, Gerald, Altmann, Bettina, Ziepert, Marita, Loeffler, Markus, and Toldbod, Helle

Published
2012
Full Text
View/download PDF

41. Nordic MCL3 Study: Zevalin Combined with High-Dose Chemotherapy Followed by Autologous Stem Cell Support As Late Intensification for Mantle Cell Lymphoma (MCL) Patients < 66 Years Not in CR After Induction Chemoimmunotherapy: No Benefit of Zevalin

Author

Arne, Kolstad, Laurell, Anna, Jerkeman, Mats, Grønbæk, Kirsten, Elonen, Erkki, Räty, Riikka, Pedersen, Lone Bredo, Loft, Annika, Bogsrud, Trond Velde, Nordstrøm, Marie, Hansen, Per Boye, Fagerli, Unn-Merete, Nilsson-Ehle, Herman, Lauritzsen, Grete Fossum, Lehmann, Anne Kristine, Sundstrom, Christer, Karjalainen-Lindsberg, Marja-Liisa, Ralfkiaer, Elisabeth, Ehinger, Mats, Delabie, Jan, Bentzen, Hans, Schildt, Jukka, Kostova-Aherdan, Kamelia, Frederiksen, Henrik, Brown, Peter de Nully, and Geisler, Christian H.

Published
2012
Full Text
View/download PDF

42. First Interim Safety Analysis of a Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated by Autologous Hematopoietic Stem Cell Transplant,

Author

d'Amore, Francesco, da Silva, Maria Gomes, Leppa, Sirpa, Relander, Thomas, Pezzutto, Antonio, Lauritzsen, Grete F., Weidmann, Eckhart, Van Gelder, Michel, Merup, Mats, Hagberg, Hans, Fagerli, Unn-Merete, Brown, Peter de Nully, Hansen, Per Boye, Mariz, Jose Mario, Jankovska, Milada, Walewski, Jan, Doorduijn, Jeanette, Van Hoof, Achiel, Christiansen, Ilse, Jyrkkiö, Sirkku, Kluin-Nelemans, J.C., van Marwijk Kooy, Marinus, Fijnheer, Rob, Stevens, Wendy, Zijlstra, Josee, Böhmer, L., Lugtenburg, P.J., Grube, Matthias, Prochazka, Vit, Salek, David, Greil, Richard, Trümper, Lorenz, Wulf, Gerald, Altmann, Bettina, Ziepert, Marita, Loeffler, Markus, Jantunen, Esa, Hopfinger, Georg, Neste, Eric Van den, and Toldbod, Helle

Published
2011
Full Text
View/download PDF

44. High-Dose Chemotherapy and Autologuos Stem Cell Transplantation in Previously Untreated Peripheral T-Cell Lymphoma - Final Analysis of a Large Prospective Multicenter Study (NLG-T-01)

Author

d'Amore, Francesco, Relander, Thomas, Lauritzsen, Grete F., Jantunen, Esa, Hagberg, Hans, Anderson, Harald, Holte, Harald, Jr., Österborg, Anders, Merup, Mats, de Nully Brown, Peter, Kuittinen, Outi, Erlanson, Martin, Østenstad, Bjørn, Fagerli, Unn-Merete, Gadeberg, Ole, Sundström, Christer, Delabie, Jan, Ralfkiaer, Elisabeth, Vornanen, Martine, and Toldbod, Helle

Published
2011
Full Text
View/download PDF

45. Favorable Outcome In ALK-Negative Anaplastic Large-Cell Lymphoma Following Intensive Induction Chemotherapy and Autologous Stem Cell Transplantation (ASCT): a Prospective Study by the Nordic Lymphoma Group (NLG-T-01)

Author

Relander, Thomas, Lauritzsen, Grete Fossum, Jantunen, Esa, Hagberg, Hans, Anderson, Harald, Cavallin-Ståhl, Eva, Holte, Harald, Østerborg, Anders, Merup, Mats, Brown, Peter De Nully, Østenstad, Bjørn, Kuittinen, Outi, Erlanson, Martin, Fagerli, Unn-Merete, Gadeberg, Ole, Sundstrom, Christer, Delabie, Jan, Ralfkiaer, Elisabeth, Vornanen, Martine, and d'Amore, Francesco

Published
2010
Full Text
View/download PDF

46. Intensive Induction Chemotherapy Followed by Autologous Stem Cell Transplantation (ASCT) In Patients with Enteropathy-Associated T-Cell Lymphoma: a Prospective Study by the Nordic Lymphoma Group (NLG-T-01)

Author

Jantunen, Esa, Relander, Thomas, Lauritzsen, Grete Fossum, Hagberg, Hans, Anderson, Harald, Cavallin-Ståhl, Eva, Holte, Harald, Østerborg, Anders, Merup, Mats, Brown, Peter De Nully, Kuittinen, Outi, Erlanson, Martin, Østenstad, Bjørn, Fagerli, Unn-Merete, Gadeberg, Ole, Sundstrom, Christer, Delabie, Jan, Ralfkiaer, Elisabeth, Vornanen, Martine, and d'Amore, Francesco

Published
2010
Full Text
View/download PDF

48. 90y-Ibritumumab Tiuxetan (Zevalin ®)-BEAM/C with Autologous Stem Cell Support as Frontline Therapy for Advanced Mantle Cell Lymphoma. – Preliminary Results From the Third Nordic MCL Phase II Study (MCL3).

Author

Kolstad, Arne, Laurell, Anna, Andersen, Niels S, Elonen, Erkki, Raty, Riikka, Pedersen, Lone Bredo, Loft, Annika, Bogsrud, Trond Velde, Nordstrom, Marie, Gillstrom, Dorte, Hansen, Per Boye, Bentzen, Hans, Fagerli, Unn-Merete, Meyer, Peter, Nilsson-Ehle, Herman, Jerkeman, Mats, Lehmann, Anne Kristine, Lauritzsen, Grete F, Sundstrom, Christer, Delabie, Jan, Karjalainen-Lindsberg, Marja-Liisa, Ralfkiaer, Elisabeth, Ehinger, Mats, and Geisler, Christian H.

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results